PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce The First Follicular Lymphoma Patient Treated with BAFF-R Targeting CAR-T Cells Achieves a Complete Response

PeproMene Bio, Inc. California

The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment.View original content:https://www.prnewswire.co.uk/news-releases/pepromene-bio-inc-and-the-institute-for-follicular-lymphoma-innovation-ifli-announce-the-first-follicular-lymphoma-fl-patient-treated-with-baff-r-targeting-car-t-cells-pmb-ct01-achieves-a-complete-response-302460432.html

@ prnewswire.co.uk